New Approaches in Immunotherapy of Behçet Disease

Shahneh, Fatemeh Zare; Mohammadian, Mohsen; Babaloo, Zohreh; Baradaran, Behzad

doi:10.5681/apb.2013.002

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it is now generally accepted that BD is an autoimmune disease, there are still studies that suggest that patients with BD have a weakened immune system and that this increases their susceptibility to COVID-19. [ 30 , 31 ] However, the mechanism of action between BD and COVID-19 is still unclear, so in this study, we screened differentially expressed genes of the 2 diseases based on bioinformatics and discovered their interrelated signaling pathways to determine the interaction between BD and COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the potential relationship between COVID-19 and Behcet’s disease using transcriptome data

et al. 2023

View full text Add to dashboard Cite

To investigate the potential role of COVID-19 in relation to Behcet's disease (BD) and to search for relevant biomarkers. We used a bioinformatics approach to download transcriptomic data from peripheral blood mononuclear cells (PBMCs) of COVID-19 patients and PBMCs of BD patients, screened the common differential genes between COVID-19 and BD, performed gene ontology (GO) and pathway analysis, and constructed the protein-protein interaction (PPI) network, screened the hub genes and performed co-expression analysis. In addition, we constructed the genes-transcription factors (TFs)-miRNAs network, the genesdiseases network and the genes-drugs network to gain insight into the interactions between the 2 diseases. We used the RNAseq dataset from the GEO database (GSE152418, GSE198533). We used cross-analysis to obtain 461 up-regulated common differential genes and 509 down-regulated common differential genes, mapped the PPI network, and used Cytohubba to identify the 15 most strongly associated genes as hub genes (ACTB,

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of the potential relationship between COVID-19 and Behcet’s disease using transcriptome data

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The primary treatment objective encompasses achieving and sustaining remission by attenuating the immune response, controlling inflammation, and averting severe complications such as vision loss. Glucocorticoids (GCS), immunosuppressants, and biologics currently serve as treatment options for BU [ 25 – 27 ]. It is important to highlight from the outset that, for patients with Behçet's Uveitis (BU) involving the posterior segment of the eye, systemic corticosteroid monotherapy is contraindicated.…”

Section: Introductionmentioning

confidence: 99%

Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches

Huang

et al. 2023

Int Ophthalmol

View full text Add to dashboard Cite

Behçet's uveitis (BU) is a debilitating manifestation of Behçet's disease, often requiring prompt and aggressive treatment to prevent vision loss. Glucocorticoids (GCS) serve as a first-line therapy for BU; however, their long-term, high-dose use can result in significant adverse effects. This review summarizes the efficacy, adverse effects, and advances in combination therapy involving GCS for the management of BU. We discuss the benefits and drawbacks of various GCS administration routes, including periocular and intravitreal injections, intravitreal sustained-release devices, and systemic therapy, highlighting the role of fluocinolone acetonide and dexamethasone as primary sustained-release formulations. Moreover, we underscore the importance of combining GCS with immunosuppressive drugs and biological agents to minimize adverse reactions and optimize therapeutic outcomes. The review concludes that, while GCS remain a crucial component of BU treatment, careful consideration of their administration and combination with other therapies is essential to achieve long-term remission and improved visual outcomes for patients with BU.

show abstract